Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fazirsiran in Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
NCT05899673Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Aug 2023
- Primary completion
- May 2033
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 5
01
Overview
A Phase 3 trial of fazirsiran in alpha-1 antitrypsin deficiency (AATD), sponsored by Takeda. Started Aug 2023; status: active, not recruiting.
02
Drugs
fazirsiran
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT05899673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05899673.